BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

INDICATION: Liver cancer Cell culture and mouse studies suggest inhibiting the HMG-CoA reductase/SQLE/LSS pathway could help treat p53-deficient liver cancer. In human liver adenocarcinoma cell lines, levels of two metabolic intermediates biosynthesized by the pathway...
BioCentury | May 4, 2018
Financial News

Medical data company Synyi.AI raises RMB100M series B

Synyi.AI (Shanghai, China) said it raised RMB100 million ($15.8 million) in a series B financing led by GGV Capital with participation from Sequoia Capital China and Zhenfund on May 1. The medical data management company...
BioCentury | May 2, 2018
Financial News

Medical data company Synyi.AI raises series B

Synyi.AI (Shanghai, China) said it raised RMB100 million ($15.8 million) in a series B financing led by GGV Capital with participation from Sequoia Capital China and Zhenfund. The medical data management company uses its machine...
BioCentury | Jul 27, 2017
Translation in Brief

Sepsis' sweet tooth

It has long been known that pathogens rely on their host to provide metabolites and metals like iron to support growth and infections. Now, scientists from the Gulbenkian Institute of Science have shown how iron...
BioCentury | Jul 18, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Mouse studies suggest ferritin or promoting FTH1 expression could help treat sepsis. In a mouse model of cecal ligation and puncture (CLP)-induced sepsis, adenoviral-mediated overexpression of FTH1 in the liver or IV injection...
BioCentury | Jun 9, 2016
Translation in Brief

Stopping sepsis

Two teams have uncovered new ways to protect against sepsis in adults and infants by targeting the body's vascular response and inflammatory response, respectively. The findings offer new therapeutic strategies for an indication with few...
BioCentury | May 26, 2014
Clinical News

CLP-1001: Completed Phase IIb enrollment

Sorbent completed enrollment of 275 patients with signs and symptoms of fluid overload following a recent heart failure-related hospitalization in the double-blind, placebo-controlled, U.S. Phase IIb STEPWISE trial evaluating twice daily 15 g CLP-1001. The...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Neurology

...and contact information Neurology Neurology Cleavage and polyadenylation factor 1 subunit 1 (CLP1) Studies in patients and mice identified a mutation in CLP1...
...dysfunction. A homozygous R140H recessive missense mutation in the gene encoding the tRNA splicing kinase CLP1...
...and motor sensory defects. In vitro, expression of the mutation decreased kinase activity, binding of CLP1...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Neurology

...in patients and zebrafish suggest increasing CLP1 expression could help treat neurodegenerative conditions caused by CLP1...
...CLP1 mRNA did not. Next steps could include developing strategies to increase expression of wild-type CLP1...
BioCentury | Jan 6, 2014
Company News

Gruenenthal, Empresas Andromaco Group deal

On Dec. 27, 2013, Gruenenthal acquired a 81.6% stake in Laboratorios Andromaco S.A . (Santiago:ANDROMACO, Santiago, Chile) for CLP332.48 per share in cash, or CLP152.1 billion ($288.2 million). Gruenenthal said it acquired all subsidiaries of the...
Items per page:
1 - 10 of 18